Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher versus standard adalimumab dosing in Crohn's disease
2013-001746-33Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in Crohn's disease (2 arms), sponsored by AbbVie Inc. Primary endpoints: Clinical remission at Week 4 and Endoscopic response at Week 12. Started Apr 2014; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2013-001746-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001746-33.